Dynamic roles of tumor-infiltrating B lymphocytes in cancer immunotherapy DOI Creative Commons
Shanshan Song,

Chong Wang,

Yangchao Chen

et al.

Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(3)

Published: Feb. 1, 2025

The amazing diversity of B cells within the tumor microenvironment is basis for diverse development cell-based immunotherapies. Here, we focus on elucidating mechanisms intervention mediated by four tumor-infiltrating lymphocytes. Naive present initial antigen, germinal center cell subsets enhance antibody affinity, and immunoglobulin subtypes exert multiple immune effects, while regulatory establish tolerance. Together they reflect complexity changing dynamics cancer immunity. Additionally, have investigated dynamic effects lymphocytes in immunotherapy their relationship to prognosis, providing new insights into potential treatment strategies patients.

Language: Английский

Tertiary lymphoid structures and B cells: An intratumoral immunity cycle DOI Creative Commons
Wolf H. Fridman, Maxime Meylan, Guilhem Pupier

et al.

Immunity, Journal Year: 2023, Volume and Issue: 56(10), P. 2254 - 2269

Published: Sept. 11, 2023

Language: Английский

Citations

116
A blueprint for tumor-infiltrating B cells across human cancers DOI
Jiaqiang Ma, Yingcheng Wu, Lifeng Ma

et al.

Science, Journal Year: 2024, Volume and Issue: 384(6695)

Published: May 2, 2024

B lymphocytes are essential mediators of humoral immunity and play multiple roles in human cancer. To decode the functions tumor-infiltrating cells, we generated a cell blueprint encompassing single-cell transcriptome, cell-receptor repertoire, chromatin accessibility data across 20 different cancer types (477 samples, 269 patients). cells harbored extraordinary heterogeneity comprised 15 subsets, which could be grouped into two independent developmental paths (extrafollicular versus germinal center). Tumor extrafollicular pathway were linked with worse clinical outcomes resistance to immunotherapy. The dysfunctional program was associated glutamine-derived metabolites through epigenetic-metabolic cross-talk, promoted T cell-driven immunosuppressive program. These suggest an intratumor balance between germinal-center responses that possibly harnessed for cell-targeting

Language: Английский

Citations

66
The effect of physical exercise on anticancer immunity DOI Open Access
Carmen Fiuza‐Luces, Pedro L. Valenzuela, Beatriz G. Gálvez

et al.

Nature reviews. Immunology, Journal Year: 2023, Volume and Issue: 24(4), P. 282 - 293

Published: Oct. 4, 2023

Language: Английский

Citations

46
Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes DOI Creative Commons
Yang Yu, Xueyan Chen,

Jieying Pan

et al.

Cell, Journal Year: 2024, Volume and Issue: 187(17), P. 4790 - 4811.e22

Published: July 23, 2024

Characterizing the compositional and phenotypic characteristics of tumor-infiltrating B cells (TIBs) is important for advancing our understanding their role in cancer development. Here, we establish a comprehensive resource human by integrating single-cell RNA sequencing data from 649 patients across 19 major types. We demonstrate substantial heterogeneity total abundance subtype composition observe immunoglobulin G (IgG)-skewness antibody-secreting cell isotypes. Moreover, identify stress-response memory tumor-associated atypical (TAABs), two tumor-enriched subpopulations with prognostic potential, shared pan-cancer manner. In particular, TAABs, characterized high clonal expansion level proliferative capacity as well close interactions activated CD4 T tumors, are predictive immunotherapy response. Our integrative depicts distinct clinically relevant TIB subsets, laying foundation further exploration functional commonality diversity cancer.

Language: Английский

Citations

34
Tertiary lymphoid structures in anticancer immunity DOI
Jean‐Luc Teillaud, Ana Houel, Marylou Panouillot

et al.

Nature reviews. Cancer, Journal Year: 2024, Volume and Issue: 24(9), P. 629 - 646

Published: Aug. 8, 2024

Language: Английский

Citations

30
Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application DOI Creative Commons
Yuyuan Zhang,

Mengjun Xu,

Yuqing Ren

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: April 6, 2024

Abstract Tertiary lymphoid structures (TLS) are clusters of immune cells that resemble and function similarly to secondary organs (SLOs). While TLS is generally associated with an anti-tumour response in most cancer types, it has also been observed act as a pro-tumour response. The heterogeneity largely determined by the composition tumour-infiltrating lymphocytes (TILs) balance cell subsets within tumour-associated (TA-TLS). TA-TLS varying maturity, density, location may have opposing effects on tumour immunity. Higher maturity and/or higher density often favorable clinical outcomes immunotherapeutic response, mainly due crosstalk between different proportions subpopulations TA-TLS. Therefore, can be used marker predict efficacy immunotherapy checkpoint blockade (ICB). Developing efficient imaging induction methods study crucial for enhancing integration techniques biological materials, including nanoprobes hydrogels, alongside artificial intelligence (AI), enables non-invasive vivo visualization TLS. In this review, we explore dynamic interactions among T B phenotypes contribute structural functional diversity TLS, examining both existing emerging induction, focusing immunotherapies biomaterials. We highlight novel therapeutic approaches being explored aim increasing ICB treatment predicting prognosis.

Language: Английский

Citations

25
RNA vaccines for cancer: Principles to practice DOI
Pablo Guasp, Charlotte Reiche, Zachary Sethna

et al.

Cancer Cell, Journal Year: 2024, Volume and Issue: 42(7), P. 1163 - 1184

Published: June 6, 2024

Language: Английский

Citations

17
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside DOI Creative Commons
Florent Peyraud, Jean‐Philippe Guégan, Lucile Vanhersecke

et al.

Med, Journal Year: 2025, Volume and Issue: 6(1), P. 100546 - 100546

Published: Jan. 1, 2025

Language: Английский

Citations

2
A Noninvasive Approach to Evaluate Tumor Immune Microenvironment and Predict Outcomes in Hepatocellular Carcinoma DOI Creative Commons
Jianmin Wu, Wanmin Liu, Xinyao Qiu

et al.

Phenomics, Journal Year: 2023, Volume and Issue: 3(6), P. 549 - 564

Published: Dec. 1, 2023

Abstract It is widely recognized that tumor immune microenvironment (TIME) plays a crucial role in progression, metastasis, and therapeutic response. Despite several noninvasive strategies have emerged for cancer diagnosis prognosis, there are still lack of effective radiomic-based model to evaluate TIME status, let alone predict clinical outcome checkpoint inhibitor (ICIs) response hepatocellular carcinoma (HCC). In this study, we developed radiomic status within the prognosis immunotherapy A total 301 patients who underwent magnetic resonance imaging (MRI) examinations were enrolled our study. The intra-tumoral expression 17 immune-related molecules evaluated using co-detection by indexing (CODEX) technology, construct Immunoscore (IS) with least absolute shrinkage selection operator (LASSO) algorithm Cox regression method TIME. Of 6115 features extracted from MRI, five core filtered out, Radiomic (RIS) showed high accuracy predicting testing cohort (area under curve = 0.753). More importantly, RIS capability anti-programmed cell death 1 (PD-1) an independent advanced HCC 0.731). comparison previously models, integrated exhibits not only higher but also potential guiding significance immunotherapy.

Language: Английский

Citations

31
Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies DOI Creative Commons

Sarah Soussan,

Guilhem Pupier, Isabelle Cremer

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Jan. 22, 2024

The intricate relationship between anti-tumor immunity and autoimmunity is a complex yet crucial aspect of cancer biology. Tumor microenvironment often exhibits autoimmune features, phenomenon that involves natural the induction humoral responses against self-antigens during tumorigenesis. This facilitated by orchestration immunity, particularly within organized structures like tertiary lymphoid (TLS). Paradoxically, significant number patients do not manifest features course their illness, with rare instances paraneoplastic syndromes. discrepancy can be attributed to various immune-mediated locks, including regulatory or suppressive immune cells, anergic autoreactive lymphocytes, effector cells exhaustion due chronic stimulation. Overcoming these locks holds risk induce mechanisms progression, notably observed anti-immune checkpoint therapies, in contrast more conventional treatments chemotherapy radiotherapy. Therefore, challenge arises managing immune-related adverse events (irAEs) induced inhibitors treatment, as decoupling them from activity poses clinical dilemma. review summarizes recent advances understanding link B-cell driven reactions patients, discusses implications this relationship.

Language: Английский

Citations

9